BR112015008177A2 - conjugados de pirrolobenzodiazepina - anticorpo - Google Patents
conjugados de pirrolobenzodiazepina - anticorpoInfo
- Publication number
- BR112015008177A2 BR112015008177A2 BR112015008177A BR112015008177A BR112015008177A2 BR 112015008177 A2 BR112015008177 A2 BR 112015008177A2 BR 112015008177 A BR112015008177 A BR 112015008177A BR 112015008177 A BR112015008177 A BR 112015008177A BR 112015008177 A2 BR112015008177 A2 BR 112015008177A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- conjugates
- pyrrolobenzodiazepine
- pyrrolobenzodiazepine conjugates
- her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| US201261712928P | 2012-10-12 | 2012-10-12 | |
| US201361784249P | 2013-03-14 | 2013-03-14 | |
| US201361784233P | 2013-03-14 | 2013-03-14 | |
| US201361784270P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2013/071343 WO2014057115A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008177A2 true BR112015008177A2 (pt) | 2017-09-19 |
Family
ID=49552324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008177A BR112015008177A2 (pt) | 2012-10-12 | 2013-10-11 | conjugados de pirrolobenzodiazepina - anticorpo |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150273077A1 (enExample) |
| EP (1) | EP2906252B1 (enExample) |
| JP (1) | JP2016502504A (enExample) |
| KR (1) | KR20150083856A (enExample) |
| CN (1) | CN104955485B (enExample) |
| AU (1) | AU2013328621B2 (enExample) |
| BR (1) | BR112015008177A2 (enExample) |
| CA (1) | CA2887896A1 (enExample) |
| CY (1) | CY1119287T1 (enExample) |
| DK (1) | DK2906252T3 (enExample) |
| ES (1) | ES2640449T3 (enExample) |
| HR (1) | HRP20171264T1 (enExample) |
| HU (1) | HUE034505T2 (enExample) |
| LT (1) | LT2906252T (enExample) |
| MX (1) | MX2015004423A (enExample) |
| PL (1) | PL2906252T3 (enExample) |
| PT (1) | PT2906252T (enExample) |
| RS (1) | RS56222B1 (enExample) |
| SI (1) | SI2906252T1 (enExample) |
| SM (1) | SMT201700444T1 (enExample) |
| WO (1) | WO2014057115A1 (enExample) |
| ZA (1) | ZA201502267B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| KR101772354B1 (ko) | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| AU2013328673B2 (en) | 2012-10-12 | 2017-07-13 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| HRP20190366T1 (hr) | 2012-10-12 | 2019-04-19 | Medimmune Limited | Pirolobenzodiazepini i njihovi konjugati |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6445519B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016037644A1 (en) * | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2015314954B2 (en) | 2014-09-12 | 2021-05-13 | Genentech, Inc. | Anti-HER2 antibodies and immunoconjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016044396A1 (en) * | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US9504694B2 (en) * | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| NZ741261A (en) | 2015-10-02 | 2019-11-29 | Genentech Inc | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| TWI726942B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| UA125198C2 (uk) * | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
| SMT202200068T1 (it) | 2017-02-08 | 2022-05-12 | Adc Therapeutics Sa | Coniugati di pirrolobenzodiazepina-anticorpo |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| WO2018193104A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| WO2018229218A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd25 adc |
| BR112020003003A2 (pt) * | 2017-08-18 | 2020-08-11 | Medimmune Limited | conjugados de pirrolobenzodiazepina |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| MX2020010110A (es) | 2018-03-28 | 2020-11-06 | Mitsubishi Tanabe Pharma Corp | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| SG11202109860VA (en) * | 2019-03-25 | 2021-10-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
| GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP4013494A1 (en) | 2019-08-12 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| US20250367307A1 (en) | 2022-06-30 | 2025-12-04 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558195C (en) * | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| AU2010265934B2 (en) * | 2009-06-26 | 2015-04-23 | Five Prime Therapeutics, Inc. | Therapeutic antibody target validation and screening in vivo |
| ES2623057T3 (es) * | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| WO2011130598A1 (en) * | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR101772354B1 (ko) * | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| SMT201900500T1 (it) * | 2011-05-08 | 2019-11-13 | Legochem Biosciences Inc | Coniugati di agente protettivo-proteina e metodo per preparare i medesimi |
| WO2013055987A1 (en) * | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 SM SM20170444T patent/SMT201700444T1/it unknown
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Withdrawn
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en not_active Ceased
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016502504A (ja) | 2016-01-28 |
| PT2906252T (pt) | 2017-09-19 |
| SI2906252T1 (sl) | 2017-10-30 |
| CY1119287T1 (el) | 2018-02-14 |
| DK2906252T3 (en) | 2017-09-11 |
| MX2015004423A (es) | 2015-10-29 |
| EP2906252A1 (en) | 2015-08-19 |
| AU2013328621A1 (en) | 2015-04-23 |
| KR20150083856A (ko) | 2015-07-20 |
| RS56222B1 (sr) | 2017-11-30 |
| WO2014057115A1 (en) | 2014-04-17 |
| CA2887896A1 (en) | 2014-04-17 |
| US20150273077A1 (en) | 2015-10-01 |
| SMT201700444T1 (it) | 2017-11-15 |
| AU2013328621B2 (en) | 2016-12-01 |
| PL2906252T3 (pl) | 2017-11-30 |
| ZA201502267B (en) | 2017-09-27 |
| ES2640449T3 (es) | 2017-11-03 |
| LT2906252T (lt) | 2017-09-11 |
| EP2906252B1 (en) | 2017-06-14 |
| CN104955485A (zh) | 2015-09-30 |
| HUE034505T2 (en) | 2018-02-28 |
| HRP20171264T1 (hr) | 2017-10-20 |
| CN104955485B (zh) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015008177A2 (pt) | conjugados de pirrolobenzodiazepina - anticorpo | |
| BR112015008173A2 (pt) | conjugados de pirrolobenzodiazepina-anticorpo anti-psma | |
| BR112015008174A2 (pt) | conjugados de pirrolobenzodiazepina-anticorpo | |
| BR112015008238A2 (pt) | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 | |
| MX2015004421A (es) | Conjugados del anticuerpo pirrolobenzodiazepina. | |
| CO7111294A2 (es) | Anticuerpo anti-fgfr2 | |
| BR112016000903A2 (pt) | anticorpos | |
| MX376976B (es) | Inmunoglobulinas heterodimericas. | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
| CR20160199A (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
| BR112017011234A2 (pt) | anticorpos contra receptor da barreira hematoencefálica e métodos de uso | |
| CO7151521A2 (es) | Anticuerpos anti-fcrn | |
| CL2015003481A1 (es) | Conjugados de anticuerpo fármaco | |
| UY34652A (es) | Anticuerpos humanos frente a toxinas de clostridium difficile | |
| PT2992016T (pt) | Terapia de combinação de um anticorpo anti-cd20 afucosilado com um conjugado anticorpo do cd79b-fármaco | |
| MX382840B (es) | Regiones de anticuerpo modificado y sus usos. | |
| CR20150284A (es) | Terapia de combinación de anticuerpos anti-her3 y anti-her2 | |
| CR20140440A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| CO7111295A2 (es) | Anticuerpo anti-rob04 | |
| MX2019003570A (es) | Agentes de union monoclonales de cmet, conjugados de farmaco de los mismos y usos de los mismos. | |
| ECSP13012481A (es) | Composiciones de anticuerpo anti-vegfr-3 | |
| EP2970503A4 (en) | MONOCLONAL ANTI- (+) - METHAMPHETAMINE ANTIBODY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01), C07K 1 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: ADC THERAPEUTICS SARL (CH) , MEDIMMUNE LIMITED (GB |
|
| B25G | Requested change of headquarter approved |
Owner name: ADC THERAPEUTICS SARL (CH) , MEDIMMUNE LIMITED (GB |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2535 DE 06-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |